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Mutations in any of the three genes coding for the extracel-
lular matrix protein collagen VI cause different types of muscle 
diseases, including Bethlem Myopathy (BM), Ullrich Congeni-
tal Muscular Dystrophy (UCMD) and Congenital Myosclero-
sis (1). Collagen VI null (Col6a1–/–) mice display a myopathic 
phenotype  with  organelle  defects,  mitochondrial  dysfunction 
and spontaneous apoptosis of muscle fibers (2). Based on the 
findings obtained in the murine model, similar defects could 
be  revealed  in  muscle  biopsies  and  cultures  of  UCMD/BM 
patients (3). Our previous studies demonstrated that one ma-
jor pathogenic event is the PTP-dependent latent mitochondrial 
dysfunction (4), however the cause for the accumulation of dys-
functional organelles remained unsolved.
The presence of swollen mitochondria and dilated sarco-
plasmic reticulum prompted to check whether the machinery 
for organelle removal, the autophagic system, is affected. We 
found that persistence of abnormal organelles and apoptosis are 
caused by defective autophagy in collagen VI deficient mus-
cles. Autophagy is a process of cytosolic ‘renovation’, which 
is essential for the maintenance of cell homeostasis by clear-
ing misfolded proteins and dysfunctional organelles. Skeletal 
muscles of Col6a1–/– mice display impaired autophagic flux, 
which matches the lower induction of Beclin 1 and Bnip3 and 
the  lack  of  autophagosomes  after  starvation.  Furthermore, 
muscle  biopsies  from  patients  affected  by  UCMD  or  BM 
show reduced levels of Beclin 1 and Bnip3. Notably, forced 
reactivation of autophagy by either genetic (overexpression 
of Beclin-1), nutritional (low protein diet) or pharmacologi-
cal (cyclosporin A) approaches restores myofiber survival and 
leads to a marked amelioration of the structural and functional 
defects of Col6a1–/– muscles, with normalization of the dys-
trophic phenotype (5, 6)
These  findings  indicate  that  defective  activation  of  the 
autophagic machinery has a key pathogenic role in congenital 
muscular dystrophies linked to collagen VI deficiency. Altogeth-
er, our data are the first demonstration that impaired autophagy 
plays a pivotal role in the pathogenesis of some muscular dys-
trophies, thus providing new insights into the pathogenesis of 
muscle degeneration and opening new perspectives for treat-
ment.
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A multidisciplinary referral clinic for the diagnosis and 
management  of  adult  patients  with  inflammatory  myopathy 
has been in operation at the ANRI in Perth since 1990. Patients 
are seen jointly by a neurologist, a clinical immunologist and 
physiotherapist and by a speech pathologist if they have swal-
lowing problems. The diagnosis of myositis is confirmed by 
muscle biopsy in all cases and screening for muscle-associated 
and muscle-specific autoantibodies is also performed. Over 250 
patients have been seen in the clinic, falling into the follow-
ing categories: inclusion body myositis (32%), dermatomyositis 
(32%), overlap syndromes (23%), isolated polymyositis (11%), 
miscellaneous (2%). Muscle function is monitored by manual 
muscle testing (MMT) and, in selected cases myometry and 
isokinetic dynamometry is performed. Patients undergo regu-
lar reviews to monitor the response to treatment. This has also 
allowed observations to be made on the frequency of relapses 
in patients with dermatomyositis and polymyositis (1), and the 
variability in the clinical phenotype and rate of progression of 
muscle  weakness  and  influence  of  HLA  alleles  in  inclusion 
body myositis (2). Two new clinical entities have been identi-
fied: statin-associated necrotising myopathy with upregulation 
of MHC-I (3), and a restricted scapulospinal form of myopathy 
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in patients with scleroderma-myositis overlap (4). New thera-
pies such as anti-B cell (rituximab) and anti-T cell (alemtuzum-
ab) monoclonal antibodies have been trialled in selected cases. 
Rituximab has been found to be beneficial in two patients with 
resistant dermatomyositis but not in a third patient with severe 
subcutaneous calcinosis.
A specialised myositis clinic allows clinicians and other 
personnel involved to develop expertise in the evaluation and 
management of this group of disorders and provides opportu-
nities for postgraduate training and research. It also makes it 
possible to develop standardised assessment and treatment pro-
tocols and to collect patient cohorts for clinical trials.
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First of all I would like to thank Prof. Giovanni Nigro and 
the organizing committee for awarding me the 2011 Gaetano 
Conte Prize, on the field of Social Aspects. I must confess that 
it was a completely unexpected surprise and the most wonderful 
thing about is the possibility to receive it in Italy, in a country 
that I love, and surrounded with very dear friends.
Although I question if I deserve this prize, it is true that 
I have always been worried with the social aspects related to 
neuromuscular disorders, in particular, living in a country where 
poor people have no access to a decent treatment. When I was 
still a master degree student I was not happy to be only in the 
laboratory and since the beginning of my research life I was 
very much involved in genetic counseling of families with neu-
romuscular disorders.
I went to UCLA in Los Angeles for my post doc and when 
I came back I decided to visit the families who I had counseled. 
I wanted to know if genetic counseling (GC) had any impact 
on their lives, if high risk carriers had deterred procreation. I 
managed to visit more than 300 families and had two surprises: 
the good one was to see that most mothers of Duchenne pa-
tients had understood the GC and very few children were born 
among those with a high genetic risk. The sad surprise was to 
see how abandoned were the older affected children from poor 
families: no wheelchair, no transportation, no conditions to at-
tend schools, physiotherapy clinics or any treatment. They were 
completely isolated from social life. I decided then that being 
just a scientist was not enough. I had to do more for these chil-
dren and I founded the Brazilian muscular dystrophy associa-
tion – ABDIM – in an attempt to improve their quality of life. 
We rented a house, remodeled it and established a center next 
to the University. Now ABDIM serves more than 100 patients 
who come twice a week and provides them with physiother-
apy, physical therapy, but also training in arts and computers: 
anything to improve life quality and expectancy. Anything to 
make them happier. In addition we have almost 1000 patients 
that come from all over Brazil every 3 to 6 months for follow-
up. And indeed life expectancy increased significantly which is 
particularly important at this moment because we hope that ex-
tending their lives will allow them to benefit of new discovered 
treatments. I am still the President of ABDIM- not because I 
want it- but because so far nobody wanted to take over. More 
recently, I was also involved in the political decisions regard-
ing the approval of the bill that allows research with embryonic 
stem cells in Brazil. On one hand, as a scientist I wanted to 
have in Brazil the same freedom for research as most devel-
oped countries. On the other hand I believed that approving this 
law would be extremely important when talking to patients and 
parents. As you know, when we tell parents that their child has 
a progressive severe disease for which the cure has not been 
found yet they would be willing to go any place in the world to 
try to find a treatment. We wanted to tell them that if the stem 
cells bill would be approved in Brazil we would be able to do 
the same research that is being done in first world countries. 
They would not need to go abroad. And I started to fight for it. 
Indeed, after many debates, the bill was definitively approved 
by our Supreme Court in 2008.
Finally, I had the great privilege to listen some years ago to 
the talk of Rita Levi Montalcini, this incredible Italian woman 
and Nobel prize scientist. It was during a Congress in United 
States. She started her talk saying that she had taken a taxi in 
Italy to reach the airport and the driver looked at her and said: I 
know you. You are a famous person. Then she asked: Why? Be-
cause of my Nobel Prize? No he replied, for your social work.
I don´t have the pretension to compare myself with Rita 
Levi. She is the woman I most admire on earth. But when I 
received the email from Giovanni Nigro I was reminded of her 
and I felt incredibly rewarded for doing social work. Initially 
from patients, from their families, and now from you my dear 
Italian friends for awarding me this prize.
Thank you very much!